评估满意地氯雷他定、盐酸非索非那定过敏的患者报告中氯雷他定的不满。

文章的细节

引用

复制到剪贴板

玻璃DJ,哈珀

评估满意地氯雷他定、盐酸非索非那定过敏的患者报告中氯雷他定的不满。

BMC Fam Pract。2003年8月13日,第四章第十节。Epub 2003年8月13日。

PubMed ID

12917016 (在PubMed

]

文摘

背景:FDA最近搬到氯雷他定(定)从处方地位场外交易(OTC)。在回应一个场外的可用性non-sedating抗组胺剂,许多管理式医疗机构重新评估,如果任何处方抗组胺药应该保持在规定的。从管理式医疗的角度来看,决定哪些剩余的处方抗组胺导致病人满意度最大的过敏治疗将是有益的。方法:加权横断面调查报告(n = 10023)交付在线过敏症患者的样本在美国在2002年12月。两段被确定为分析:患者不满意氯雷他定,转换成地氯雷他定(药;n = 61),患者不满意氯雷他定,转换成盐酸非索非那定(爱兰歌娜;n = 211)。两段比较一系列措施,相关文献表明治疗满意度。结果:调查发现,两个满意的措施有区别地氯雷他定转换器从盐酸非索非那定转换器(p < . 05):意味着自我报告的不良事件和夜间觉醒由于过敏症状。满意的其余部分措施,患者不满意氯雷他定报告相同时间的覆盖率和满意地氯雷他定的盐酸非索非那定。 When severity of disease was controlled for in the analysis, a pattern emerged suggesting greater levels of satisfaction amongst loratadine dissatisfied patients who converted to desloratadine. Point estimates suggest a consistent pattern favoring desloratadine patient satisfaction, with statistically significant results reported for sum of adverse effects, nighttime awakening due to symptoms, symptom severity just prior to the next dose, and overall satisfaction (p < 0.05). CONCLUSIONS: On average, patients who were dissatisfied with loratadine reported equal or better satisfaction with desloratadine as fexofenadine. Patients with severe allergic rhinitis reported greater satisfaction when converted from loratadine to desloratadine than fexofenadine for select satisfaction measures. These results suggest that if managed care intends to position prescription antihistamines as second line for OTC loratadine treatment dissatisfaction, desloratadine is a useful treatment alternative. These findings, while informative to formulary decision-makers, must be interpreted with caution. Only through head-to-head controlled clinical trials can differences in efficacy and safety be established.

beplay体育安全吗DrugBank数据引用了这篇文章

药物

地氯雷他定